檢索結果 - David S. Mendelson
- Showing 1 - 20 results of 22
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
-
6
Randomized, Phase II Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Soft Tissue Sarcoma 由 Laurence H. Baker, Eric K. Rowinsky, David S. Mendelson, Rod Humerickhouse, Raymond A. Knight, Jiang Qian, Robert Carr, Gary Gordon, George D. Demetri
出版 2008Artigo -
7
Case Report: Lung Disease in World Trade Center Responders Exposed to Dust and Smoke: Carbon Nanotubes Found in the Lungs of World Trade Center Patients and Dust Samples 由 Maoxin Wu, Ronald E. Gordon, Robin Herbert, María L. Padilla, Jacqueline Moline, David S. Mendelson, Virginia R. Litle, William D. Travis, Joan Gil
出版 2009Artigo -
8
Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma 由 Jimmy J. Hwang, John Kuruvilla, David S. Mendelson, Michael J. Pishvaian, John F. Deeken, Lillian L. Siu, Mark S. Berger, Jean Viallet, John L. Marshall
出版 2010Artigo -
9
Adjuvant and Salvage Radiotherapy After Prostatectomy: American Society of Clinical Oncology Clinical Practice Guideline Endorsement 由 Stephen J. Freedland, R. Bryan Rumble, Antonio Finelli, Ronald C. Chen, Susan F. Slovin, Mark N. Stein, David S. Mendelson, Colin Wackett, Howard M. Sandler
出版 2014Revisão -
10
A Prospective, Cross-sectional Survey Study of the Natural History of Niemann-Pick Disease Type B 由 Margaret M. McGovern, Melissa Wasserstein, Roberto Giugliani, Bruno Bembi, Marie T. Vanier, Eugen Mengel, Scott E. Brodie, David S. Mendelson, Gwen Skloot, Robert J. Desnick, Noriko Kuriyama, Gerald F. Cox
出版 2008Artigo -
11
Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors 由 William P. Tew, Michael S. Gordon, John R. Murren, Jakob Dupont, S. Pezzulli, Carol Aghajanian, Paul Sabbatini, David S. Mendelson, Lawrence Schwartz, Scott Gettinger, Amanda Psyrri, Jesse M. Cedarbaum, David R. Spriggs
出版 2009Artigo -
12
A Roadmap for Foundational Research on Artificial Intelligence in Medical Imaging: From the 2018 NIH/RSNA/ACR/The Academy Workshop 由 Curtis P. Langlotz, Bibb Allen, Bradley J. Erickson, Jayashree Kalpathy‐Cramer, Keith Bigelow, Tessa S. Cook, Adam E. Flanders, Matthew P. Lungren, David S. Mendelson, Jeffrey D. Rudie, Ge Wang, Krishna Kandarpa
出版 2019Artigo -
13
Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer 由 David B. Agus, Michael S. Gordon, Charles Taylor, Ronald B. Natale, Beth Y. Karlan, David S. Mendelson, Michael F. Press, David E. Allison, Mark X. Sliwkowski, Gracie Lieberman, Stephen M. Kelsey, Gwen Fyfe
出版 2005Artigo -
14
A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer 由 Lee S. Rosen, Herbert I. Hurwitz, Michael K. Wong, Jonathan W. Goldman, David S. Mendelson, William D. Figg, Shawn D. Spencer, Bonne J. Adams, Delia Alvarez, Ben K. Seon, Charles P. Theuer, Bryan R. Leigh, Michael S. Gordon
出版 2012Artigo -
15
An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer 由 Michael S. Gordon, Francisco Robert, Daniela Matei, David S. Mendelson, Jonathan W. Goldman, E. Gabriela Chiorean, Robert Matthew Strother, Ben K. Seon, William D. Figg, Cody J. Peer, Delia Alvarez, Bonne J. Adams, Charles P. Theuer, Lee S. Rosen
出版 2014Artigo -
16
Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progress... 由 David B. Agus, Christopher J. Sweeney, Michael J. Morris, David S. Mendelson, Douglas G. McNeel, Frederick R. Ahmann, Jin Wang, Mika K. Derynck, Kimmie Ng, Benjamin Lyons, David E. Allison, Michael W. Kattan, Howard I. Scher
出版 2007Artigo -
17
Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advan... 由 Michael S. Gordon, Christopher J. Sweeney, David S. Mendelson, S. Gail Eckhardt, Abraham Anderson, Darrin M. Beaupre, Daniel Branstetter, Teresa L. Burgess, Angela Coxon, Hongjie Deng, Paula Kaplan‐Lefko, Ian M. Leitch, Kelly S. Oliner, Lucy Yan, Min Zhu, Lia Gore
出版 2010Artigo -
18
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab 由 Nancy U. Lin, Eric P. Winer, Duncan Wheatley, Lisa A. Carey, Stephen Houston, David S. Mendelson, Pamela N. Münster, Laurie Frakes, Steve Kelly, Agustin A. García, Susan Cleator, Martina Uttenreuther‐Fischer, H. Jones, Sven Wind, Richard Vinisko, Tamas Hickish
出版 2012Artigo -
19
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer 由 Johanna C. Bendell, Michael S. Gordon, Herbert I. Hurwitz, Suzanne F. Jones, David S. Mendelson, Gerard C. Blobe, Neeraj Agarwal, Carolyn H. Condon, Dawn Wilson, Amelia E. Pearsall, Yijun Yang, Ty McClure, Kenneth M. Attie, Matthew L. Sherman, Sunil Sharma
出版 2013Artigo -
20
Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline 由 D.A. Loblaw, Katherine S. Virgo, Robert K. Nam, Mark R. Somerfield, Edgar Ben‐Josef, David S. Mendelson, Richard Middleton, Stewart A. Sharp, Thomas J. Smith, James A. Talcott, Mary‐Ellen Taplin, Nicholas J. Vogelzang, James L. Wade, Charles L. Bennett, Howard I. Scher
出版 2007Revisão
相關主題
Medicine
Internal medicine
Oncology
Cancer
Adverse effect
Clinical trial
Gastroenterology
Pathology
Pharmacokinetics
Pharmacology
Chemotherapy
Phases of clinical research
Biology
Breast cancer
Immunology
Nausea
Prostate cancer
Tolerability
Toxicity
Antibody
Cancer research
Disease
Guideline
Pharmacodynamics
Regimen
Androgen deprivation therapy
Androgen receptor
Angiogenesis
Artificial intelligence
Bevacizumab